Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients

Koh,Youngil; Kim,Dae-Young; Park,Sung-Hyo; Byun,Hyang-Min; Kim,Inho; Yoon,Sung-Soo; Kim,Byoung   Kook; Park,Eunkyung; Yang,Allen  s.; Park,Seonyang

doi:10.3892/ol.2010.208

January-February 2011 Volume 2 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-February 2011 Volume 2 Issue 1

Full Size Image

Article

Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients

Authors:
- Youngil Koh
- Dae-Young Kim
- Sung-Hyo Park
- Hyang-Min Byun
- Inho Kim
- Sung-Soo Yoon
- Byoung Kook Kim
- Eunkyung Park
- Allen s. Yang
- Seonyang Park
View Affiliations / Copyright

Affiliations: Department of Internal Medicine, Seoul National University Hospital, Seoul National University, Seoul, Korea, Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea, Diagnostic DNA Chip Center, Seoul National University, College of Medicine, Seoul, Korea, Jane Anne Nohl, Division of Hematology, University of Southern California, Los Angeles, CA, USA, The Korean Society of Hematology, CML Working Party, Seoul, Korea, Jane Anne Nohl, Division of Hematology, University of Southern California, Los Angeles, CA, USA
Pages: 181-187
|
Published online on: November 23, 2010

https://doi.org/10.3892/ol.2010.208
Expand metrics +

Abstract

To define the correlation between BCR promoter DNA methylation and response to imatinib in chronic myeloid leukemia (CML), we investigated BCR promoter DNA methylation in three groups of subjects. The first group included chronic phase patients enrolled in an imatinib dose escalation trial. In the trial, patients who failed to achieve optimal response with 400 mg/day (suboptimal responders) received an escalated imatinib dose. The level of BCR promoter DNA methylation was quantitated at baseline six months after dose escalation. The second group included patients who achieved complete cytogenetic remission after receiving 400 mg/day of imatinib (optimal responders), and the third group were the healthy controls. In the suboptimal responders, an increased BCR promoter DNA methylation at six months compared with the baseline was related to a rapid reduction in the BCR-ABL/ABL transcript level following dose escalation (p=0.001) and a longer time to treatment failure (TTFx) of the dose-escalated imatinib (p=0.008). When multivariate analysis was performed with regard to the baseline BCR-ABL transcript level, baseline BCR promoter DNA methylation, and a change in the BCR promoter DNA methylation following dose escalation, the increase in the BCR promoter DNA methylation following dose escalation was an independent predictive factor for TTFx of dose-escalated imatinib (hazard ratio, 0.294; p=0.015). The baseline BCR promoter DNA methylation level in the suboptimal responders was lower than that in BCR promoter DNA methylation in the optimal responders (p=0.001) and healthy controls (p<0.001). In both the optimal and suboptimal responders, BCR promoter DNA methylation had an inverse correlation with the duration of the 400 mg/day imatinib use. In conclusion, increased BCR promoter DNA methylation strongly correlates with a more favorable imatinib response in CML patients.

View Figures

View References

1	Goldman JM and Melo JV: BCR-ABL in chronic myelogenous leukemia – how does it work? Acta Haematol. 119:212–217. 2008.
2	Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 5:172–183. 2005. View Article : Google Scholar : PubMed/NCBI
3	Wen ST and Van Etten RA: The PAG gene product, a stress- induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11:2456–2467. 1997. View Article : Google Scholar : PubMed/NCBI
4	McWhirter JR, Galasso DL and Wang JY: A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 13:7587–7595. 1993.PubMed/NCBI
5	Pendergast AM, Muller AJ, Havlik MH, et al: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 66:161–171. 1991. View Article : Google Scholar : PubMed/NCBI
6	Issa JP, Kantarjian H, Mohan A, et al: Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 93:2075–2080. 1999.PubMed/NCBI
7	Sun B, Jiang G, Zaydan MA, et al: ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors. Cancer Res. 61:6931–6937. 2001.PubMed/NCBI
8	Zion M, Ben-Yehuda D, Avraham A, et al: Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 91:10722–10726. 1994. View Article : Google Scholar : PubMed/NCBI
9	Shtivelman E, Lifshitz B, Gale RP, et al: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:550–554. 1985. View Article : Google Scholar : PubMed/NCBI
10	Jiang G, Yang F, Li M, et al: Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. Cancer Biol Ther. 2:103–108. 2003. View Article : Google Scholar : PubMed/NCBI
11	Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 108:1809–1820. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hughes T: ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program. 211–218. 2006. View Article : Google Scholar : PubMed/NCBI
13	Hochhaus A and Hughes T: Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 18:641–656. 2004. View Article : Google Scholar : PubMed/NCBI
14	Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.PubMed/NCBI
15	Koh Y, Kim I, Yoon SS, et al: Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann Hematol. 89:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
16	Yang AS, Estecio MR, Doshi K, et al: A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 32:e382004. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles